 acelRx Pharmaceuticals, Inc. (NASDAQ:ACRX ) reported a net loss of $9.7 million or $0.21 basic and diluted net loss per share for the fourth quarter and year ended 2016. 
 this net loss compares to net loss of $10.5 million or $0.24 basic and diluted net income per share for the fourth quarter of 2015. for the full year ended, 2016, we reported a net loss of $0.2 million or $0.095 basic and diluted net loss per share, compared to net loss of $0.4 million or $0.060 basic and diluted net loss per share for the same period in 2015.    during the fourth quarter we submitted a new drug application or nda to the U.S. Food and Drug Administration for a 30 microgram sublingual sufentanil tablet for the the treatment of adult patients experiencing moderate to severe acute pain in a medically supervised setting.    during the fourth quarter 
 we also completed a series of presentations at medical conferences including the international society for burn injuries, the annual meeting of the American Society of Plastic Surgeons, the European Conference on Emergency Medicine, the National Conference on